- Home
- LXEO vs VERU Comparison
LXEO vs VERU Comparison
Compare LXEO & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- VERU
- Stock Information
- Founded
- LXEO 2017
- VERU 1971
- Country
- LXEO United States
- VERU United States
- Employees
- LXEO N/A
- VERU N/A
- Industry
- LXEO
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- LXEO
- VERU Health Care
- Exchange
- LXEO Nasdaq
- VERU Nasdaq
- Market Cap
- LXEO 93.9M
- VERU 85.5M
- IPO Year
- LXEO 2023
- VERU 1990
- Fundamental
- Price
- LXEO $4.49
- VERU $0.60
- Analyst Decision
- LXEO Strong Buy
- VERU Strong Buy
- Analyst Count
- LXEO 5
- VERU 2
- Target Price
- LXEO $16.60
- VERU $4.00
- AVG Volume (30 Days)
- LXEO 520.2K
- VERU 2.5M
- Earning Date
- LXEO 08-11-2025
- VERU 08-07-2025
- Dividend Yield
- LXEO N/A
- VERU N/A
- EPS Growth
- LXEO N/A
- VERU N/A
- EPS
- LXEO N/A
- VERU N/A
- Revenue
- LXEO N/A
- VERU $16,886,419.00
- Revenue This Year
- LXEO N/A
- VERU N/A
- Revenue Next Year
- LXEO N/A
- VERU N/A
- P/E Ratio
- LXEO N/A
- VERU N/A
- Revenue Growth
- LXEO N/A
- VERU 134.43
- 52 Week Low
- LXEO $1.45
- VERU $0.45
- 52 Week High
- LXEO $19.50
- VERU $1.42
- Technical
- Relative Strength Index (RSI)
- LXEO 63.76
- VERU 50.99
- Support Level
- LXEO $3.91
- VERU $0.54
- Resistance Level
- LXEO $4.85
- VERU $0.60
- Average True Range (ATR)
- LXEO 0.33
- VERU 0.04
- MACD
- LXEO 0.02
- VERU -0.01
- Stochastic Oscillator
- LXEO 78.69
- VERU 31.05
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.